After bDMARD treatment for 1 year in AxSpA, the gut microbiota composition: ◦ more resembled controls ◦ Enrichment of Collinsella remained stable ◦ Depletion of some species in HLA-B27+ patients from baseline https://t.co/Mw4MToqFcQ Poddubnyy et al @ProftDr #ACR22 @RheumNow

• Improvement of Gut Microbiota Dysbiosis in Patients with Axial Spondyloarthriti…

#ACR22 Abs 0256 identified different autoantibodies in ACPA+ and ACPA– RA. Study shows potential utility of serum autoantibodies as diagnostic targets for RA subgroups & treatments. This study reminds me of @RheumNow teaching that not all RA created equal. https://t.co/Fjjk6uC0pB https://t.co/Ozr32cJojr

• Patients with ACPA-positive and ACPA-negative Rheumatoid Arthritis Show Differe…

“It's not that I'm so smart, it's just that I stay with problems longer.” Einstein Love the quote in the community hub for early career @NIAMSFunding - Perseverance is the KEY in this funding world #ACR22 @RheumNow

Figueroa-Parra et al @AliDuarteMD Preventative services in SLE better in some areas and worse in some than comparators. Overall cervical screening, osteoporosis, dyslipidaemia low in this high risk group @rheumnow #ACR22 Abstr#0064 https://t.co/fHQ7ct6yt5 https://t.co/x7gHUDA8zo

• Utilization of Preventive Services in a Systemic Lupus Erythematosus Population…

Wilding et al. Mortality in AAV 1/5/10-year survival 90%/73%/57% in AAV, 97%/86%/73% controls (p <0.0001). Highest 1st year - often vasculitis related (35%). After this - infection (28% vs 19%) @rheumnow #ACR22 Abstr#0448 https://t.co/YwwaaB6jDS https://t.co/ogrJkLAd1v

• All-Cause and Cause-Specific Mortality in ANCA-Associated Vasculitis: A Populat…

Good news for patients who require short interruptions in biologic therapy! Majority of axSpA patients (82%) who restarted ixekizumab after withdrawing, achieved low disease activity and 68% eventually had inactive disease. #Abs0427 @RheumNow #ACR22

Hajj-Ali @RulaHajjAliMD et al. Worse PROs neuro AAV. Lower SF-36 Physical Functioning, Limitations in Physical role, Bodily Pain, and PCS. Higher PROMIS pain, lower PROMIS function @rheumnow #ACR22 Abstr#0437 https://t.co/ldC2VEZ0FV https://t.co/0pdjdSZQSS

• Outcome Measures in Patients with Neurologic Involvement in ANCA-associated Vas…

Ab0192: UPA vs ADA vs PBO on RAPID3 in SELECT-PsA (bio-naive, P3 trial) #ACR22 UPA>ADA from wk 16-56. UPA and ADA>>PBO Strongly associates with DAPSA or MDA/VLDA composite scores @RheumNow https://t.co/ABY12ar7RS

Kakoullis et al. Steroid initiation within 1 week onset of GCA symptoms associated decreased relapse OR=0.216. @rheumnow #ACR22 Abstr#0469 https://t.co/sEW1V6NRpb https://t.co/4sAYZbmHX3

• Factors Associated with Corticosteroid Dosing in the Management of Giant Cell A…

Korean KOBIO-AS registry: Infection incidence 26 events/1000 PY (URI > zoster most common) Risks: ischemic heart disease, ASDAS-ESR >3.5, complicated DM, abnormal chest x-ray, current bDMARDs. Male gender was protective. Abs 0372 #ACR22 @RheumNow https://t.co/i1JyFuriFz

• Incidence and Risk of Overall Infections in Patients with Ankylosing Spondyliti…

Christ et al. 1 year follow up of GUSTO - tocilizumab monotherapy in GCA after 3 days only of steroid. Week 52 - 13/18 in relapse free remission. Week 104 12/18 in relapse free remission @rheumnow #ACR22 Abstr#0470 #ACRbest https://t.co/Pnvoeqb8rp https://t.co/dB6F25Krgg

• Long-term Efficacy of Tocilizumab Monotherapy After Ultra-short Glucocorticoid …

Gomez et al. RA patient derived ACPAs both prevent and ameliorate collagen-antibody induced arthritis when given at early but not late stage in an animal model. Appears to be mediated through NETs @rheumnow #ACR22 Abstr#0045 https://t.co/HSD0oZBaha https://t.co/OqTv4XLXws

• Rheumatoid Arthritis Patient-derived Anti-citrullinated Protein Antibodies (ACP…

Bui et al. Screening for ANCA in ILD. Present in 9.8% . 65.4% of these had AAV. No difference in pulmonary outcomes. More steroids, immunosuppressives, hospitalisations. @rheumnow #ACR22 Abstr#0438 https://t.co/RGdnDWSpNF https://t.co/xYeCUoTqqy

• Characterization of Interstitial Lung Disease in the Presence of Antineutrophil…

Endothelin-1, pro-inflammatory protein involved in multiple vascular and fibrosing abnormalities, may be a biomarker for differentiating between IPF and IIM-ILD or SSc-ILD. I'm always interested in potential biomarkers for clinic! Abs 0123 #ACR22 @RheumNow https://t.co/I69X4V0Zoa

• Increase of Serum Endothelin-1 Levels in Patients with Interstitial Lung Diseas…

BIOBADASER cohort showing risk of incident cancer in rheumatic disease and previous malignancy was not difference between TNFi and other biologics/tsDMARDs. Need bigger numbers (esp with JAKi) to really reassure. @RheumNow ABST0267 #ACR22 #ACRBest https://t.co/0YutuCBOb8 https://t.co/btYrCA6UDh

• Cancer Risk with Biologic and Targeted Synthetic DMARDs in Patients with Rheuma…